Ra Pharmaceuticals to Present at the Jefferies 2016 Complement Therapeutics Summit

CAMBRIDGE, Mass.--()--Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and orphan indications defined by validated biomarkers, today announced that Doug Treco, PhD, President and Chief Executive Officer, will present at the Jefferies 2016 Complement Therapeutics Summit on Tuesday, May 3, 2016 at 10:45 a.m. E.T. The conference is being held at the Jefferies Conference Center in New York.

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and orphan indications defined by validated biomarkers. The Company’s proprietary Extreme Diversity™ peptide chemistry platform delivers drugs with the diversity and specificity of antibodies, coupled with the pharmacological properties of small molecules. RA101495, the Company’s lead synthetic macrocyclic peptide inhibitor of complement C5, is currently in Phase 1 development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). For more information, please visit: www.rapharma.com.

Contacts

Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com

Recent Stories

RSS feed for Ra Pharmaceuticals